Hemab Therapeutics Holdings, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
COAG Nasdaq 2836 www.hemab.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - May 27th, 2026 6:00 am
Hemab Therapeutics Reports First Quarter 2026 Financial Results - May 21st, 2026 5:00 am
Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - May 4th, 2026 2:01 pm
Hemab Therapeutics IPO Debut Puts COAG And Pipeline Risks In Focus - May 3rd, 2026 1:07 am
Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering - Apr 30th, 2026 4:55 pm